# Effects of Tetrahydrobiopterin (BH4) on Leg Blood Flow and Exercise Capacity in Patients With Peripheral Artery Disease

> **NCT03493412** · PHASE4 · WITHDRAWN · sponsor: **University of Nebraska**

## Conditions studied

- Peripheral Artery Disease
- Peripheral Arterial Disease

## Interventions

- **DRUG:** Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03493412
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-07-01
- **Primary completion:** 2019-07-01
- **Final completion:** 2019-10-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** discontinued due to change in operating plans prior to study initiation and enrollment
- **Last updated:** 2024-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03493412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03493412, "Effects of Tetrahydrobiopterin (BH4) on Leg Blood Flow and Exercise Capacity in Patients With Peripheral Artery Disease". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03493412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*